Action BINV BIOINVENT INTERNATIONAL AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues BioInvent International AB

Actions

BINV

SE0015244520

Temps réel estimé Cboe Europe
Autres places de cotation
 09:30:30 30/04/2024 		Varia. 5j. Varia. 1 janv.
25,92 SEK +2,47 % Graphique intraday de BioInvent International AB +9,83 % +35,55 %
24/04 BioInvent International AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
03/04 BioInvent, Merck & Co. signent un essai clinique et un accord d'approvisionnement pour le traitement des tumeurs en complément de Keytruda. MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BioStock: BioInvent selected to present at ASCO in Chicago
BioInvent International AB, Interim report January-March 2024
BioInvent Q1 2024 - Approaching Catalysts
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024
BioInvent International AB: Interim report January-March 2024
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024
BioInvent International AB publishes Annual Report 2023
BioStock: BioInvent deepens collaboration with MSD
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
Notice to Annual General Meeting in BioInvent International AB
BioStock: BioInvent's CEO comments on the study success in China
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
BioInvent International AB Year-end report January 1, December 31, 2023
BioInvent Q4 2023 - Now a mid-stage clinical company
BioInvent International AB Year-end report January 1 – December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BINV
  4. Actualités BioInvent International AB
  5. Autres langues